GINZA NOA CLINIC
Tokyo, Japan International Patient Support
Contact Us

What Are Class II Regenerative Treatments?

In Japan, Class II regenerative treatments are procedures in the middle regulatory risk category under the Act on the Safety of Regenerative Medicine. Class II is not a particular cell type, a treatment for one disease, or a grade of effectiveness 4980. Before providing a Class II treatment, the clinic must obtain review by a specified certified committee and submit a provision plan to the Minister of Health, Labour and Welfare Plan.

Class II accounted for 2,463 of Japan’s 6,743 treatment plans on file as of 30 June 2026, about 36.5% 001590173.pdf. That proportion describes filed plans, not the likelihood that a treatment will help you.

What Are Class II Regenerative Treatments?

What Class II Means

The Act on the Safety of Regenerative Medicine (Act No. 85 of 2013) sorts covered techniques into three risk groups 4980:

  • Class I: Faces the strictest watch — effects on life and health are unclear, or serious harm remains possible even with careful work.
  • Class II: Sits in the middle — health risks remain possible even with careful work, but the technique falls outside the Class I group.
  • Class III: Covers everything else under the law — techniques that are neither Class I nor Class II.

How Common Is Class II

MHLW counted 2,463 Class II treatment plans as of 30 June 2026. The figures below are dated snapshots for Japan, not live totals.

Figure Value Date and source
Treatment plans on file 6,743, plus 85 research plans As of 30 June 2026 001590173.pdf
Class II share 2,463 plans, about 36.5% of treatment plans Same report; Class I 8 (about 0.1%), Class III 4,272 (about 63.4%) 001590173.pdf
Approved regenerative products 26 active (28 cumulative minus one withdrawal and one expiry), including gene therapies and cell- or tissue-based products As of 20 May 2026 000280868.pdf
Framework currency Amended law in force since 31 May 2025, bringing certain in vivo gene therapies into the Safety Act as Class I MHLW regional bureau notice Saisei_top_00005

These are plan counts, not counts of clinics, patients, or successful treatments. Class II was the second-largest treatment-plan group, behind Class III 001590173.pdf. Product approvals use a different legal route and unit of measurement; dividing product approvals by plan filings would not give an approval rate or a chance of benefit.

Why the Same Cells Can Fall Into Different Classes

A cell name alone does not establish the class. The classification depends on the technique and the ministry’s risk-classification rules, including the cell source, processing, and intended use Plan. Here, “Class II” refers specifically to Japan’s framework; do not assume the same term in another country’s materials has the same legal meaning.

Treatments that use only an approved regenerative product within its approved uses fall under a different law for product approval. Ask the clinic which legal route your exact treatment uses Index.

How Class II Differs From Class I and Class III

If you are comparing offers, the class sets the review path. It does not rank how well treatments work 4980 Plan.

Feature Class I Class II Class III
Risk idea in the law Effects unclear, or risk of serious effects even with care Risk of effects on life and health even with care, but not Class I Covered techniques that are neither Class I nor Class II
Committee Specified certified committee, plus a national-level check with a waiting period before treatment can start Specified certified committee Certified committee (standard level)

Only Class I adds a national-level check and a waiting step; neither step measures success rates.

What You Would Actually Receive

There is no single Class II treatment protocol. Ask for the exact cell source, processing method, dose, number of sessions, and administration route in the current plan. If an offer involves cultured cells, ask where they are processed and request the cell-processing facility‘s applicable permission, notification, or certification details. A facility’s regulatory status is not evidence that the proposed treatment works Plan.

Read the registration and compliance terminology separately from descriptions of treatments grouped by condition in the regenerative medicine overview. Neither a condition name nor a cell name identifies the exact procedure offered.

What Must Happen Before a Class II Offer

For a Class II offer, three checkpoints come first:

  1. The clinic prepares a provision plan describing the treatment, the cells, the processing, the safety steps, and the consent papers.
  2. A specified certified committee reviews the plan and issues a written opinion.
  3. The clinic submits the plan to the Minister of Health, Labour and Welfare. It then treats patients under the law’s standards, with duties for explanation and consent, record-keeping, and problem reporting Plan.

Non-research plans go through the e-Regenerative Medicine system. Research plans under the same law use jRCT. Plan changes requiring advance submission must first receive committee review; minor changes must be notified within 10 days Plan. Ask where your current documents fit in the treatment process, particularly if the proposed procedure has changed since the original consultation.

What Class II Does Not Tell You

Not an Effectiveness Grade

Class II is not “better” than Class III, nor “almost as good” as Class I. The classes describe regulatory risk categories and determine oversight requirements, not success rates or a numerical probability of harm 4980.

Not a Product Approval

Japan approves regenerative medical products through a separate product-approval route. The regulator reported 26 approved regenerative products as of 20 May 2026. That group includes gene therapies and cell- or tissue-based products. It is not a count of private stem-cell treatments 000280868.pdf. A clinic’s plan filing alone does not turn its preparation into an approved product.

Not Proof of Benefit

A plan number or trial registration alone does not establish benefit, durability, or safety for your condition. Evidence must identify the product or procedure, the people treated, the study design, and the outcomes measured.

A U.S. approval illustrates the distinction; it is not an example of a Japanese Class II clinic treatment. On 18 December 2024, the FDA approved Ryoncil (remestemcel-L-rknd), an allogeneic bone-marrow-derived mesenchymal stromal cell therapy, for steroid-refractory acute graft-versus-host disease in children aged 2 months and older after donor transplantation. The multicenter, single-arm study included 54 children receiving intravenous infusions twice weekly for four weeks. At day 28, 16 had complete responses (30%) and 22 had partial responses (41%). There was no concurrent comparison group. Common adverse reactions included infections, fever, hemorrhage, edema, abdominal pain, and hypertension Fda approves first mesenchymal stromal cell therapy treat steroid refractory acute graft versus host.

Those day-28 responses do not establish long-term benefit or support arthritis, fatigue, or anti-aging uses. For any Class II offer, ask whether published studies match your diagnosis, disease stage, cell type and source, dose, route, and follow-up needs.

How to Check a Class II Claim

If a clinic tells you its offer is Class II, take the plan number, committee name, and institution details from the clinic’s papers and check them against official records; screenshots in a sales brochure are not enough.

  • Get the exact treatment name. It should match the plan — a vague phrase like “stem cell therapy” is not enough.
  • Get the plan number and current papers. Ask for the filed plan, its filing or update date, the committee’s written opinion, the cell-processing facility’s applicable permission, notification, or certification details, and the explanation and consent forms Plan.
  • Match the details. Your diagnosis and eligibility, cell source, whether cells are cultured, dose and dosing method, number of sessions, and route should line up across the quote, the plan, and the consent form.
  • Separate the roles. The treating clinic, the cell-processing facility, and any agent or payment company can be different groups. Write down who does what, who handles emergencies, and who you call afterward.
  • Start from the official portal. The ministry’s regenerative medicine pages link to the filing systems and current guidance Index. Research-side entries can be checked in the national trial registry En top. If you cannot find the record yourself, ask the clinic for the current official record and a way to confirm it through the responsible authority.

Do not sign or pay anything non-refundable until the papers line up and you understand the risks, choices, costs, and follow-up. The brochure name may not match the filed plan word for word, so lay the quote, the plan, and the consent form side by side and keep a copy of each version you were given.

A Document-Matching Example

Suppose a quote offers an intravenous infusion, but the plan supplied describes a joint injection. This is a hypothetical paperwork mismatch, not a patient case. Ask the clinic to identify the current plan covering the infusion and explain the discrepancy in writing before you consent. Even after the documents match, ask separately for evidence of benefit and risks for your condition.

Risks and Follow-Up in Class II Care

Class II does not mean risk-free. Ask the clinician to explain the risks of cell collection, processing, and administration for the exact procedure, and to distinguish observed adverse events from possible or still-unknown risks. Request the number of people followed, follow-up duration, serious adverse events, and reasons anyone stopped treatment. The framework requires explanation and consent, record-keeping, and adverse-event reporting; a class label cannot replace that discussion Plan.

Ask who monitors you afterward, which symptoms require urgent assessment, how emergency care is arranged, and who pays for it. If you travel, get a written handover and contact plan for care after you return home.

Ask whether the offer is clinical care or a research study. Neither self-payment nor registration tells you the strength of the evidence. A testimonial cannot establish how likely you are to benefit. Discuss established treatment options with your own physician before changing or delaying care, and reject promises of guaranteed results.

Questions to Ask About a Class II Offer

Ask for the answers in writing about that Class II offer, with the plan number and document version cited.

  1. Which current filed plan covers the exact treatment you are offering me, and what is its number, risk class, and filing date?
  2. Which committee reviewed it, and were there conditions attached to the opinion?
  3. What cells, processing steps, dose, sessions, and route does the plan specify for someone with my diagnosis and stage?
  4. What published results match my situation — including comparison group, follow-up length, and side effects — and what remains unknown?
  5. What is the full cost, what does each session include, what follow-up is planned, and who is responsible if something goes wrong?

Have a plan number or clinic quote you want to double-check? You can send your questions through our contact page.

Contact Us

Bottom Line

Class II means a middle-risk regulatory category in Japan, with specified-committee review and a provision-plan filing, not proof of effectiveness 4980 Plan. It represented about 36.5% of treatment plans on file in the 30 June 2026 snapshot 001590173.pdf. Check any claim of product approval separately against the regulator’s list of approved regenerative medical products 0002. Before deciding with your treating doctor, establish three things: which current plan covers the exact procedure, what evidence matches your condition, and who is responsible for follow-up and complications.

General information only — not personal medical advice. Diagnosis, eligibility, and treatment decisions rest with the physician who examines you.

References

  1. Act on the Safety of Regenerative Medicine (Act No. 85 of 2013), English text — definitions of Class I, II, and III regenerative medicine technology (Art. 2). https://www.japaneselawtranslation.go.jp/en/laws/view/4980
  2. Ministry of Health, Labour and Welfare — provision-plan submission and procedures. https://www.mhlw.go.jp/stf/seisakunitsuite/bunya/kenkou_iryou/iryou/saisei_iryou/plan.html
  3. MHLW report — 6,743 treatment plans (8 Class I, 2,463 Class II, 4,272 Class III) and 85 research plans as of 30 June 2026. https://www.mhlw.go.jp/content/001590173.pdf
  4. PMDA presentation — 26 approved regenerative medical products as of 20 May 2026. https://www.pmda.go.jp/files/000280868.pdf
  5. MHLW (Kinki Regional Bureau of Health and Welfare) — amended Safety Act in force 31 May 2025, adding certain in vivo gene therapies as Class I. https://kouseikyoku.mhlw.go.jp/kinki/iji/saisei/saisei_top_00005.html
  6. Ministry of Health, Labour and Welfare — regenerative medicine portal (Safety Act vs. product-approval routes). https://www.mhlw.go.jp/stf/seisakunitsuite/bunya/kenkou_iryou/iryou/saisei_iryou/index.html
  7. U.S. Food and Drug Administration — press announcement, FDA approves Ryoncil (remestemcel-L-rknd) for steroid-refractory acute graft-versus-host disease, 18 December 2024. https://www.fda.gov/news-events/press-announcements/fda-approves-first-mesenchymal-stromal-cell-therapy-treat-steroid-refractory-acute-graft-versus-host
  8. Japan Registry of Clinical Trials (jRCT) — national registry run for notification procedures including implementation plans under the Act on the Safety of Regenerative Medicine; use the search page to check research-side entries. https://jrct.mhlw.go.jp/en-top
  9. Pharmaceuticals and Medical Devices Agency — List of Approved Products: New Regenerative Medical Products (April 2015 to July 2026), English information page. https://www.pmda.go.jp/english/review-services/reviews/approved-information/0002.html